Black, Asian, and Hispanic members of the U.S. Armed Forces were far less likely than their white comrades to undergo knee replacement surgeries after being diagnosed with osteoarthritis (OA), military researchers found.
All News
A Swedish study examine the genetic contribution to various rheumatic/musculoskeletal diseases (RMDs) and showed that osteoarthritis (OA) had a large heritability compared with other RMDs.
Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.
Curcumin is widely used in traditional Chinese medicine to treat arthritis and is presumed to have analgesic and antiinflammatory effects that may benefit those with osteoarthritis, particularly knee osteoarthritis (KOA).
Sarcopenia commonly has been linked to aging and arthritis and contributes significantly to quality of life and outcomes, but the association between sarcopenia and OA has not been well established.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery.
Arthritis & Rheumatology has published a new study that suggests knee or hip osteoarthritis patients who are overweight or obese may have less premature death if slow to moderate rate of weight loss results from anti-obesity medications.
The role of thromboprophylaxis following total hip (THA) or total knee arthroplasty (TKA) is uncertain and consensus is lacking. A recent study suggests that thromboprophylaxis strategies should be tailored to individual risk of thrombosis and bleeding.
The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral presentations. Here’s a list of the late breakers; below, I provide commentary on the ones that caught my attention.
GNSC-001 gene therapy w/ a recombinant adeno-assoc. viral vector expressing IL-1Ra, to block IL-1. GNSC-001 now in a phase Ib, 50 pt, 10 center USA trial to assess its efficacy in Knee OA. Given as single injx in the affected joint; results in late 2024 https://t.co/jW9FHlGyC2 https://t.co/Dbv15Flqlv
